Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

31 May 2010

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Targeted Genetics Corporation announced that its partner, Celladon Corporation, presented full data today that show the first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

31 May 2010

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

Nephrologists must consider fluid overload effects when prescribing dialysis, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology. The fluid overload biomarker, N-terminal pro-brain-type natriuretic peptide, previously known as a "cardiac biomarker" in dialysis patients, is an important component of managing patients with kidney disease.

28 May 2010

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

BG Medicine, Inc., a U.S. based, privately-held biomarker discovery and in vitro diagnostics company, announced today that there will be several data presentations regarding galectin-3 at the Heart Failure Congress 2010, the annual scientific meeting of the Heart Failure Association of the European Society of Cardiology, to be held in Berlin, Germany, on May 29th through June 1st. BG Medicine has developed and applied for FDA clearance of an in vitro diagnostic test to measure galectin-3 levels in plasma or serum.

28 May 2010

Pressure BioSciences signs CRADA with AFIP, ARP and VA

Pressure BioSciences, Inc. today announced that it has signed a Cooperative Research and Development Agreement ("CRADA") with the Armed Forces Institute of Pathology ("AFIP"), the American Registry of Pathology ("ARP"), and the Department of Veterans Affairs ("VA").

27 May 2010

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. This study is part of a major drug-development program to evaluate an innovative new treatment to reduce recurrent cardiovascular events associated with acute coronary syndrome.

27 May 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.

26 May 2010

RCSI researchers identify biomarker that can predict severity of breast cancer

Researchers from the Royal College of Surgeons in Ireland have identified a biomarker in patient blood which can predict the severity of breast cancer in patients and may enable clinicians to track patients throughout the course of their treatment.

26 May 2010

Agilent Technologies, Stemina Biomarker Discovery to accelerate metobolomic research

Agilent Technologies Inc. and Stemina Biomarker Discovery, Inc. today announced efforts to accelerate Stemina's metobolomic research. Stemina uses metabolomic analysis of stem cells for the discovery of biomarkers for use in drug screening and drug development.

25 May 2010

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Agilent Technologies Inc. today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

25 May 2010

Phase 1 clinical trial of OXY111A initiated

NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.

24 May 2010

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for vilazodone for the treatment of major depressive disorder.

24 May 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.

24 May 2010

New England Peptide launches NEPTune line of custom proteomics reagents

New England Peptide (NEP) today introduced NEPTune TM, a new proprietary line of custom proteomics reagents to help its customers to quickly and inexpensively maximize biomarker assay development and produce consistent results.

21 May 2010

Blood biomarker underscores role of inflammation in vascular disease

UC Davis researchers have discovered that a blood component linked with inflammation can predict coronary artery disease in African-Americans.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients

Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous administration of JX-594 to patients with metastatic cancer. The data presented today demonstrated clear dose-related delivery to solid tumors, cancer-targeted replication and gene expression, and anti-cancer effects of JX-594 delivered IV.

21 May 2010

Rosetta Genomics announces publication of study on discovery of microRNAs in solid tumors

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostic tests, announces the publication of a study entitled, "Discovery of microRNAs and other small RNAs in solid tumors," in the online edition of Nucleic Acid Research.

19 May 2010

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

In the most comprehensive study to date, neurologists have clearly identified significant differences in the ways that Alzheimer's disease affects patients with and without the apolipoprotein E ε4 gene, a known genetic risk factor for the neurodegenerative disease, using a combination of cognitive and neuroanatomic measures. The study found that this gene influences the way the disease manifests, even at its mildest clinical stages.

19 May 2010

Biomarker News and Research

Further Reading

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Cardiac biomarkers help nephrologists manage fluid overload in dialysis patients: Study

BG Medicine announces data presentations on galectin-3 at Heart Failure Congress 2010

Pressure BioSciences signs CRADA with AFIP, ARP and VA

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

VisEn Medical announces launch of two new imaging agents at EMIM 2010

RCSI researchers identify biomarker that can predict severity of breast cancer

Agilent Technologies, Stemina Biomarker Discovery to accelerate metobolomic research

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Phase 1 clinical trial of OXY111A initiated

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

2010 ASCO Annual Meeting highlights new research findings on cancer

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

New England Peptide launches NEPTune line of custom proteomics reagents

Blood biomarker underscores role of inflammation in vascular disease

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Positive results from Phase 1 study evaluating IV administration of JX-594 to metastatic cancer patients

Rosetta Genomics announces publication of study on discovery of microRNAs in solid tumors

Study examines impact of APOE ε4 on cognitive function, brain anatomy in AD patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News